Premium
Clinical impact of antibody formation to botulinum toxin A in children
Author(s) -
Herrmann Jochen,
Geth Katrin,
Mall Volker,
Bigalke Hans,
Schulte Mönting Jürgen,
Linder Michaela,
Kirschner Jan,
Berweck Steffen,
Korinthenberg Rudolf,
Heinen Florian,
Fietzek Urban M.
Publication year - 2004
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20098
Subject(s) - antibody , botulinum toxin , neutralizing antibody , medicine , toxin , titer , antibody titer , clostridium botulinum , immunology , gastroenterology , anesthesia , biology , microbiology and biotechnology
We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long‐term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse ( p < 0.001). The most significant risk factors for antibody formation were the frequency of treatments ( p = 0.0001) and the injection of a higher weight‐adapted maximum dose per treatment ( p = 0.001).